<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695630</url>
  </required_header>
  <id_info>
    <org_study_id>30779</org_study_id>
    <secondary_id>U54DE014254</secondary_id>
    <secondary_id>T32007132</secondary_id>
    <nct_id>NCT00695630</nct_id>
  </id_info>
  <brief_title>Flumazenil Reversal of Oral Triazolam</brief_title>
  <official_title>Flumazenil Rescue Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increase in the utilization of anesthesia and sedation medications by
      non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in
      part, by the need for pharmacological tools to address high levels of fear and anxiety about
      dental care among the US population and the evidence of oral health disparities among those
      who are fearful . Given the prevalence of dental fear in the general population and in the
      various populations with the greatest burden of oral diseases, effective sedation techniques
      are needed that are safe and effective in the hands of general dentists that make up the
      &quot;front line&quot; in the efforts to reduce oral health disparities. This study is to determine
      whether, when compared to a saline placebo, a single intraoral submucosal administration of
      the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or
      less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual
      dosing of triazolam (3 doses of 0.25 mg over 90 minutes).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observer Assessment of Alertness/Sedation</measure>
    <time_frame>360 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BIS</measure>
    <time_frame>360 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Dental Anxiety</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flumazenil 2mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline, 2mL SM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumazenil</intervention_name>
    <description>2 mL, 0.2 mg SM</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mL sterile saline SM</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I

        Exclusion Criteria:

          -  Use of benzodiazepines, anxiolytics or any other medications that would interact with
             either triazolam's or flumazenil's metabolism or clinical effect (including herbals)
             within four weeks of the study

          -  Body mass index (BMI) no less than 15 kg/m2 and no greater than 30 kg/m2

          -  Pregnancy or not currently using pharmacologic methods of birth control

          -  Allergy or sensitivity to benzodiazepines

          -  History of a seizure disorder; AND

          -  Chronic tobacco use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter M Milgrom, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dental Fears Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jackson DL, Milgrom P, Heacox GA, Kharasch ED. Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. J Clin Psychopharmacol. 2006 Feb;26(1):4-8.</citation>
    <PMID>16415697</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <last_update_submitted>June 11, 2008</last_update_submitted>
  <last_update_submitted_qc>June 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Peter Milgrom/Professor of Dental Public Health Sciences</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>conscious sedation</keyword>
  <keyword>dental anxiety/drug therapy</keyword>
  <keyword>behavior/drug effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

